Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study (Q35552265)
Jump to navigation
Jump to search
scientific article published on December 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study |
scientific article published on December 2003 |
Statements
1 reference
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study (English)
1 reference
G R Burmester
1 reference
L B A van de Putte
1 reference
R Rau
1 reference
F C Breedveld
1 reference
J R Kalden
1 reference
M G Malaise
1 reference
P L C M van Riel
1 reference
M Schattenkirchner
1 reference
H Zeidler
1 reference
H M Moutsopoulos
1 reference
K Beck
1 reference
H Kupper
1 reference
1 December 2003
1 reference
1 reference
62
1 reference
12
1 reference
1168-1177
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference